Disclosure of Directors' and Officer's Relevant Interests

Section 19T, Securities Markets Act 1988

A. Disclosure obligation (tick box to note which disclosure obligation applies)

Initial disclosure (complete Parts A, B, C, D, F, and G of this notice)

~

Ongoing disclosure (complete Parts A, B, C, E, F, and G of this notice)

B. Preliminary

1.	Name	Mr Graeme Howie
2.	Name of issuer	Neuren Pharmaceuticals Limited
3.	Name of related body corporate (if applicable)	N/A
4.	Position you hold in the issuer	Director
5.	Date of this disclosure notice	2 May 2006

C. Nature of relevant interest

6.	Name of registered holder(s) of security (as requested by regulation 6A(b) or regulation 7(b))	Mrs Janet Mary Howie
7.	Class and type of security (as required by regulation 6B or regulation 8)	Ordinary Shares
8.	5 .	Relevant interest as director of Neuren Pharmaceuticals Limited and spouse of registered holder

D. Date (for initial disclosure)

9.	Date	of	disclosure	obligation	(as	N/A
	requir	required by regulation 6C)				

E. Transaction (for ongoing disclosure)

10.	Date of last disclosure (as required by regulation 13)	14 March 2005
11.	Date(s) of acquisition(s) or disposal(s) (as required by regulation 9)	21-28 April 2006
12.	Number of transactions (as required by regulation 12(2), if applicable)	25,000 Ordinary Shares
13.	Nature or type of transaction (as required by regulation 11(1)(a))	Ordinary Shares
14.	Consideration (as required by regulation 10)	A\$13,629.69

15.	Number of securities held prior, set out by class and type (as required by regulation 8)	50,000
16.	Number of securities subject to acquisition or disposal (as required by regulation 11(1)(b))	NIL

F. Extent of relevant interest

17.	Number of securities held now, set out	75,000 Ordinary Shares
	by class and type (as required by	
	regulation 6B or regulation 8)	

G. Signature

18.	Signature (as required by regulation 14)	